Anti-Müllerian hormone – clinical use and future possibilities

Czech version

Authors: O. Dubová ; Michal Zikán
Authors‘ workplace: Gynekologicko-porodnická klinika 1. LF UK a FN Bulovka, Praha
Published in: Ceska Gynekol 2023; 88(2): 126-130
Category: Review Article
doi: https://doi.org/10.48095/cccg2023126

Overview

Anti-Müllerian hormone (AMH) is a protein produced already in human fetus. It has an essential role in the differentiation of the reproductive tract, regulation of the ovaries and testes. The determination of serum AMH levels is used in clinical practice. Today, especially in reproductive medicine in the assessment of ovarian reserve and in the prediction of the response to ovarian stimulation. However, in young cancer patients, it can also predict the risk of ovarian failure after anticancer treatment. It finds further use in pediatric endocrinology in the diagnosis of sexual differentiation disorders. In oncology, it is used as a tumor marker for monitoring patients with granulosa tumors. In the future, however, it is also promising to use the knowledge of AMH function for the treatment of gynecological as well as other solid malignancies expressing a tissue-specific receptor for AMH.

Keywords:

endometrial cancer – ovarian cancer – BRCA – anti-Müllerian hormone – AMHRII – murlentamab

Sources

1. Shrikhande L, Shrikhande B, Shrikhande A. AMH and its clinical implications. J Obstet Gynaecol India 2020; 70 (5): 337–341. doi: 10.1007/s13224-020-01362-0.

2. Kim JH, MacLaughlin DT, Donahoe PK. Mullerian inhibiting substance/anti-Müllerian hormone: a novel treatment for gynecologic tumors. Obstet Gynecol Sci 2014; 57 (5): 343–357. doi: 10.5468/ogs.2014.57.5.343.

3. Oh SR, Choe SY, Cho YJ. Clinical application of serum anti-Müllerian hormone in women. Clin Exp Reprod Med 2019; 46 (2): 50–59. doi: 10.5653/cerm.2019.46.2.50.

4. Dewailly D, Andersen CY, Balen A et al. The physiology and clinical utility of anti-Müllerian hormone in women. Hum Reprod Update 2014; 20 (3): 370–385. doi: 10.1093/humupd/dmt 062.

5. Gowkielewicz M, Lipka A, Piotrowska A et al. Anti-Müllerian hormone expression in endometrial cancer tissue. Int J Mol Sci 2019; 20 (6): 1325. doi: 10.3390/ijms20061325.

6. Borahay MA, Lu F, Ozpolat B et al. Mullerian inhibiting substance suppresses proliferation and induces apoptosis and autophagy in endometriosis cells in vitro. ISRN Obstet Gynecol 2013; 2013: 361489. doi: 10.1155/2013/361489.

7. Namkung J, Song JY, Jo HH et al. Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis. J Clin Endocrinol Metab 2012; 97 (9): 3224–3230. doi: 10.1210/jc.2012-1538.

8. Goodman LR, Goldberg JM, Flyckt RL et al. Effect of surgery on ovarian reserve in women with endometriomas, endometriosis and controls. Am J Obstet Gynecol 2016; 215 (5): 589.e1–589.e6. doi: 10.1016/j.ajog.2016.05.029.

9. Rumpíková T, Štelcl M, Vencálek O et al. Faktory ovlivňující sérovou hladinu anti-Müllerian hormonu. Ceska Gynekol 2018; 83 (5): 324–328.

10. Anderson RA, Rosendahl M, Kelsey TW et al. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer 2013; 49 (16): 3404–3411. doi: 10.1016/j.ejca.2013.07.014.

11. Cobo A, García-Velasco JA, Coello A et al. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril 2016; 105 (3): 755.e8–764.e8. doi: 10.1016/ j.fertnstert.2015.11.027.

12. Roness H, Spector I, Leichtmann-Bardoogo Y et al. Pharmacological administration of recombinant human AMH rescues ovarian reserve and preserves fertility in a mouse model of chemotherapy, without interfering with anti-tumoural effects. J Assist Reprod Genet 2019; 36 (9): 1793–1803. doi: 10.1007/s10815-019-01507-9.

13. Renaud EJ, MacLaughlin DT, Oliva E et al. Endometrial cancer is a receptor-mediated target for Müllerian inhibiting substance. Proc Natl Acad Sci U S A 2005; 102 (1): 111–116. doi: 10.1073/pnas.0407772101.

14. Barbie TU, Barbie DA, MacLaughlin DT et al. Mullerian inhibiting substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci U S A 2003; 100 (26): 15601–15606. doi: 10.1073/pnas. 2636900100.

15. Hoshiya Y, Gupta V, Segev DL et al. Mullerian inhibiting substance induces NFkB signaling in breast and prostate cancer cells. Mol Cell Endocrinol 2003; 211 (1–2): 43–49. doi: 10.1016/ j.mce.2003.09.010.

16. Parry RL, Chin TW, Epstein J et al. Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo. Cancer Res 1992; 52 (5): 1182–1186.

17. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. 2022 [online]. Verze 7.0 [2007], ISSN 1802-8861. Dostupné z: http: //www.svod.cz.

18. Howlader N, Krapcho M, Miller D et al. SEER Cancer Statistics Review, 1975–2018. 2018 [online]. Dostupné z: https: //seer.cancer.gov/csr/1975_2018.

19. Zhang T, Deng L, Xiong Q et al. Anti-Müllerian hormone inhibits proliferation and induces apoptosis in epithelial ovarian cancer cells by regulating the cell cycle and decreasing the secretion of stem cell factor. Oncol Lett 2018; 16 (3): 3260–3266. doi: 10.3892/ol.2018.8 985.

20. Stephen AE, Pearsall LA, Christian BP et al. Highly purified mullerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res 2002; 8 (8): 2640–2646.

21. Pieretti-Vanmarcke R, Donahoe PK, Szotek P et al. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res 2006; 12 (5): 1593–1598. doi: 10.1158/1078-0432.CCR-05-2108.

22. Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA et al. Mullerian inhibiting substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A 2006; 103 (46): 17426–17431. doi: 10.1073/pnas.0607959103.

23. Ha TU, Segev DL, Barbie D et al. Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism. J Biol Chem 2000; 275 (47): 37101–37109. doi: 10.1074/jbc.M005701200.

24. Nam SW, Jo YS, Eun JW et al. Identification of large-scale characteristic genes of Müllerian inhibiting substance in human ovarian cancer cells. Int J Mol Med 2009; 23 (5): 589–596. doi: 10.3892/ijmm_00000168.

25. Masiakos PT, MacLaughlin DT, Maheswaran S et al. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res 1999; 5 (11): 3488–3499.

26. Prat M, Salon M, Allain T et al. Murlentamab, a low fucosylated Anti-Müllerian Hormone type II Receptor (AMHRII) antibody, exhibits anti-tumor activity through tumor-associated macrophage reprogrammation and T cell activation. Cancers (Basel) 2021; 13 (8). doi: 10.3390/cancers13081845.

27. Phillips KA, Collins IM, Milne RL et al. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Hum Reprod 2016; 31 (5): 1126–1132. doi: 10.1093/humrep/dew044.

28. Wang ET, Pisarska MD, Bresee C et al. BRCA1 germline mutations may be associated with reduced ovarian reserve. Fertil Steril 2014; 102 (6): 1723–1728. doi: 10.1016/j.fertnstert. 2014.08.014.

29. Giordano S, Garrett-Mayer E, Mittal N et al. Association of BRCA1 mutations with impaired ovarian reserve: connection between infertility and breast/ovarian cancer risk. J Adolesc Young Adult Oncol 2016; 5 (4): 337–343. doi: 10.1089/jayao.2016.0009.

30. Michaelson-Cohen R, Mor P, Srebnik N et al. BRCA mutation carriers do not have compromised ovarian reserve. Int J Gynecol Cancer 2014; 24 (2): 233–237. doi: 10.1097/IGC.000 0000000000058.

31. Johnson L, Sammel MD, Domchek S et al. Antimullerian hormone levels are lower in BRCA2 mutation carriers. Fertil Steril 2017; 107 (5): 1256.e6–1265.e6. doi: 10.1016/j.fertn- stert.2017.03.018.

32. Oktay KH, Bedoschi G, Goldfarb SB et al. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency. Fertil Steril 2020; 113 (6): 1251.e1–1260.e1. doi: 10.1016/ j.fertnstert.2020.01.033.

33. Turan V, Lambertini M, Lee DY et al. Association of germline BRCA pathogenic variants with diminished ovarian reserve: a meta-analysis of individual patient-level data. J Clin Oncol 2021; 39 (18): 2016–2024. doi: 10.1200/JCO.20.02880.